Mingchao Kang

Mingchao Kang

Company: Ambrx

Job title: Project Leader


Dr. Kang received his Ph.D. in Chemistry at the Scripps Research Institute in the laboratory of Dr. Peter G. Schultz, who is the co-founder of Ambrx, Inc. Then he was trained as a postdoc in the Inder Verma group at the Salk Institute. He is currently leading multiple oncology projects at Ambrx by harnessing the power of introducing nonnative amino acids through an expanded genetic code to generate novel biotherapeutics.  


Live Discussion & Question Time 2:40 pm

Read more

day: Day Two

Tumor-Targeted Delivery of a TLR7 Agonist by Site-Specific Antibody-Drug Conjugate 2:20 pm

• TLR agonist therapies are largely restricted to intratumoral administration due to systemic toxicity • Ambrx has developed a platform to enable tumor targeted delivery of a TLR7 agonist via homogenous, site-specific antibody-drug conjugate (ADC) • Review how tumor-targetedTLR7 agonist ADCs induce potent anti-tumor immune responses and outperform systemically administered TLR7 agonistRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.